AIP

Arteris is a genuinely high-quality semiconductor-IP franchise hiding inside a stretched stock. The business sells NoC interconnect and SoC-integration IP at a 90.2% gross margin, grew FY2025 revenue 22.3% to $70.6M, and — critically — flipped operating cash flow positive to $6.73M (from ~$0.6M) against just $1.39M of capex, so it is now self-funding at the cash level. Forward visibility is real: management reports $77.0M Annual Contract Value ($83.6M including royalties) and 83 Confirmed Design Starts in 2025, and the January 2026 Cycuity acquisition (up to $45M) adds hardware-security IP to the portfolio. This is not a broken company; on operations it is executing.

The problem is price, not quality. At $47.36 the market cap is $2.15B, or 30.5x trailing revenue, and that is after today's +9.40% move. A 22%-grower deserves a premium, but 30x sales is a multiple usually reserved for 40%+ growers with clear profitability — and Arteris is neither. The income statement is still deeply red: operating margin -47.0%, net margin -49.2%, a $34.7M net loss that has NOT improved despite five straight years of revenue growth (losses were -$23.4M in FY2021 and are larger today). R&D alone ($49.9M) is 71% of revenue, and the MDA itself flags one-to-three-year product cycles and six-to-nine-month sales cycles with 'no assurance' of return — i.e., spending is structurally front-loaded and lumpy.